Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-24T10:53:26.108Z Has data issue: false hasContentIssue false

13 - Non-Inferiority Trials

from Section 3

Published online by Cambridge University Press:  05 May 2012

By
Rick Chappell
Edited by
Bernard Ravina ,
Jeffrey Cummings ,
Michael McDermott  and
R. Michael Poole
Bernard Ravina
Affiliation:
Biogen Idec., Cambridge, MA
Jeffrey Cummings
Affiliation:
Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas
Michael McDermott
Affiliation:
University of Rochester
R. Michael Poole
Affiliation:
AstraZeneca PLC, Waltham, MA, US
Get access

Summary

This chapter mentions multi-arm randomized trials in multiple hypothesis testing and non-inferiority trials with more than two treatments. Randomization is as central to the conduct of noninferiority as it is to superiority trials. Well-defined endpoints, clearly prioritized and stated in advance, are important components of powerful trials yielding useful results. As with most aspects of the analysis of a randomized clinical trial, the standard to which the worst performance of the treatment vs. the control is to be compared should be specified in advance. Non-inferiority trials can make useful scientific contributions when ethical considerations disallow a placebo or other inactive control. However, unlike the scenario of a superiority trial with a placebo, their assay sensitivity is not directly ensured by randomized comparison and so there are numerous cautions in their use. The measures of study quality mentioned in key comparisons between superiority and noninferiority trials are examined.

Keywords

neurological disorderspharmacodynamic biomarkersanimal CNS disease modelsCNS drug developmentcentral nervous systemblood brain barrier
Type
Chapter
Information
Clinical Trials in Neurology
Design, Conduct, Analysis
 , pp. 135 - 146
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×